BrightPath Biotherapeutics Company

BrightPath Biotherapeutics Co., Ltd., was established in 2003, with the mission of developing cancer peptide vaccines, which constitute one form of cancer immunotherapy. However, the field has expanded considerably since that time.

Investors

Industry: Genomic and Epigenominc Instabillity
Headquarters: Japan
N/A
Register and Claim Ownership